Search

everythinglearnresearchcommunity

for

Search:↓

Dexamethasone mini-pulse therapy is effective for alopecia areata but less effective for those with early onset or hypothyroidism.

Baricitinib is effective and safe for treating severe alopecia areata, promoting significant hair regrowth.

Omalizumab is generally safe for chronic urticaria, but hair loss is a common side effect.

Migrants from certain regions had a higher risk of COVID-19 than Spaniards.

Alopecia areata in Spain has a significant impact with unmet treatment needs and high costs.

Alopecia areata severely impacts quality of life, causing anxiety, depression, and work impairment.

Alopecia areata causes a significant economic burden in Japan, mainly due to productivity loss.

A high neutrophil-to-lymphocyte ratio may predict poor response to hair loss treatment.

Janus kinase inhibitors help some people with severe alopecia areata regrow hair, but not everyone responds, and relapses can happen.

Using 5-alpha reductase inhibitors may lower prostate cancer risk in people with androgenetic alopecia.

Scalp microinfusion with dutasteride is a safe and promising treatment for male hair loss.

PRP-based treatments can increase hair density, but results vary among individuals.

Ritlecitinib is effective and safe for treating severe alopecia areata, showing significant hair regrowth and improved mental health.

Using 5-alpha reductase inhibitors may lower prostate cancer risk in people with androgenetic alopecia.

GLP-1RA therapy may increase the risk of hair loss.

Eyebrow and eyelash hair loss in alopecia areata worsens quality of life.

Finasteride use may increase suicidality risk, especially in young men.

The combination of TACE and Donafenib is effective and tolerable for treating unresectable liver cancer.

Baricitinib effectively and safely improves hair growth in patients with severe alopecia areata.

Tofacitinib is effective for treating alopecia areata, and starting treatment early may improve results.

Japanese patients and physicians often disagree on the severity of Alopecia Areata and treatment satisfaction, needing better communication and treatments.

Comprehensive screening for infections is crucial before starting JAK inhibitors in alopecia areata patients.

Baricitinib was effective and safe for severe hair loss treatment over 6 months.

Growth factor concentrate therapy helps manage hair loss.

Clofazimine effectively treated ashy dermatosis in a patient.

Fremanezumab effectively reduces migraines and improves quality of life with mild side effects.

Higher monocyte counts may predict poor response to adalimumab in hidradenitis suppurativa patients.

Houttuynia cordata extract promotes hair growth and could be useful in hair care products.